Clinical Trials

1 studies in IgG4-related disease

1. Rituximab in IgG4-related Disease: A Phase 1-2 Trial Rochester, MN View Summary
   Close

   Rituximab in IgG4-related Disease: A Phase 1-2 Trial

   Location:

   Rochester, MN

   Trial status:

   Open for Enrollment

   Why is this study being done?

   This two-center trial will enroll at total of 30 patients with IgG4-RD. The two participating sites are the Massachusetts General Hospital (Boston, MA) and the Mayo Clinic (Rochester, MN). All patients will receive rituximab 1 gram intravenously times two doses, separated by approximately 15 days. The primary efficacy outcome - disease remission and successful completion of the glucocorticoid taper - will be assessed at six months. Patients will be followed on the protocol for an additional six months after measurement of the primary outcome.

   NCT ID:

   NCT01584388

   • Print Summary
   • View study details

   Who can I contact for additional information about this study?

   Rochester: Mark Topazian, MD 507-284-7602
                       Lori A Bergstrom, RN 507-538-1887